Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04455958
Other study ID # STUDY00021444
Secondary ID NCI-2020-02877ST
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date May 1, 2021
Est. completion date November 1, 2021

Study information

Verified date April 2021
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir/ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.


Description:

PRIMARY OBJECTIVE: I. To determine if treatment with lopinavir/ritonavir will decrease progression of symptoms compared to control/placebo. SECONDARY OBJECTIVES: I. Determine if treatment improves time to symptom resolution. II. Determine the time to symptom progression. III. Determine time to improvement of participants as defined by complete resolution of symptoms. IV. Determine the proportion of participants who have severe or critical symptoms and hospital admission. V. Determine the time to hospital admission for those who develop severe of critical symptoms VI. Determine the proportion of participants with an intensive care unit (ICU) admission. VII. Determine the proportion of participants receiving ventilator support. VIII. Determine survival of participants enrolled on the study. EXPLORATORY OBJECTIVES: I. For patients admitted to the hospital, will determine the following parameters: potassium level, blood oxygen level, creatinine, and blood pressure. II. Identify obstacles and barriers encountered while implementing a clinical trial in the context of a pandemic caused by a contagious disease and associated social distancing. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive lopinavir/ritonavir orally (PO) twice daily (BID) for 14 days in the absence of disease progression or unacceptable toxicity. GROUP II: Patients receive placebo PO BID for 14 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up 3 times a week until symptoms resolve plus 2 additional weeks thereafter, for up to 3 months, whichever occurs first.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 1, 2021
Est. primary completion date November 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ability to understand and the willingness to sign a written informed consent document - Participants with a diagnostically proven COVID-19 positive nasal swab test result within 14 days - Participants must have a diagnosis of cancer - Participants must be considered immune suppressed either due to their cancer diagnosis or due to treatment of their cancer. Participants must meet at least one of the following criteria: - Have received immune suppressing anti-cancer therapy in the past year (i.e., therapy that suppresses white blood cells and/or has been shown to be associated with infection, as stipulated in the drug package insert) - Have received intravenous immunoglobulin (IVIG) in the past year for treatment and/or prevention of recurrent infections - Are within one year of an autologous bone marrow transplant or chimeric antigen receptor (CAR) T-cell therapy, or within five years of an allogeneic bone marrow transplant - Have been treated for three or more infections within the past 6 months - Have an absolute neutrophil count at or below 1,500 cells/mcL at some point within two months of the time of consent. This can be due therapy and/or due to cancer suppressing marrow function - Have a history of neutropenic fever in the past year - Presence of a chronic infection, e.g. tuberculosis (TB) or osteomyelitis, or within 3 months of treatment for such. Topical fungal infections of the skin are not included in this category - Participants with mild symptoms, must have had mild symptoms for no more than 2 weeks - Participants with moderate symptoms, must have had moderate symptoms for no more than 1 week - Pregnant or women of child-bearing potential may be treated if they have no documented lopinavir-associated resistance substitutions - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x upper limit of normal (ULN) - Total bilirubin =< 2 x ULN (individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis) - Creatinine =< 2 x ULN - Participants with abnormal blood counts (white blood cell [WBC], platelet, hemoglobin [Hg]) will not be excluded Exclusion Criteria: - Participants who do not develop mild to moderate symptoms within 28 days of test results - Participants with rapid clinical deterioration, in the opinion of the investigator - Participants experiencing severe symptoms according to COVID-19 Symptom Grading Tool - History of being human immunodeficiency virus (HIV) positive; by history only; participants do not need to confirm by testing - Participant has any other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, may cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol - Participants receiving any contraindicated medication that in the opinion of the investigator cannot be continued while receiving study drug and cannot be held for the duration of the 14-day study treatment period safely - History of unstable cardiac disease in the past 6 months - History of prolonged QT interval, or on other cardiac medications known to prolong the QT interval - Use of strong inhibitors and inducers of CYP3A4 is prohibited. Lopinavir/ritonavir (L/R) is primarily metabolized by CYP3A4. Therefore, concomitant use of strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nelfinavir and saquinavir), and inducers of CYP3A (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort) are not permitted. The use of other herbals will be reviewed on a case-by-case basis. If they are deemed to be strong modulators of CYP3A4, patients will be excluded if they are unable or unwilling to stop taking them - Women who plan to breast feed while on this study are not eligible for participation due to the potential for unnecessary adverse event risks to a child

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lopinavir/Ritonavir
Given PO
Placebo Administration
Given PO
Other:
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute Oregon Health and Science University

Outcome

Type Measure Description Time frame Safety issue
Other Potassium level Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test. 3 months
Other Blood oxygen level Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test. 3 months
Other Creatinine level Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test. 3 months
Other Blood pressure Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test. 3 months
Other Ability to remotely consent, monitor, and treat patients in the context of a pandemic of a contagious disease Will evaluate on a subjective basis the ability to remotely consent, monitor and treat patients in the context of a pandemic of a contagious disease. The proportion of participants able to be remotely consented, monitored, and treated in the context of a pandemic of a contagious disease will be tabulated and compared using the chi-square test. 3 months
Primary Severity of symptoms Will be compared to the time of randomization. The severity of symptoms will be categorized as mild, moderate, severe, or critical according to the grading of symptoms. The proportion of participants with progression to more severe symptoms between treatments groups will be compared using a Fisher's Exact test at a 0.05 significance level. 3 months
Secondary Clinical benefit rate of lopinavir/ritonavir Will be defined as improvement on symptoms: yes or no. Will be compared between treatment groups using log-rank test. A 95% confidence interval of treatment rate difference in symptom progression will be calculated by the Wald method. 3 months
Secondary Time to symptom progression Will be compared between treatment groups using log-rank test. From randomization to the first documented symptoms progression, assessed up to 3 months
Secondary Time to improvement of participants Will be compared between treatment groups using log-rank test. From randomization to first documented complete resolution of symptoms, assessed up to 3 months
Secondary Time to hospital admission for those who develop severe of critical symptoms Will be compared between treatment groups using log-rank test. From time of randomization to the time of hospital admission, assessed up to 3 months
Secondary Intensive care unit (ICU) admission: yes or no Will be compared using Fisher's exact test, and point and interval estimates will be provided. 3 months
Secondary Receiving ventilator support: yes or no Will be compared using Fisher's exact test, and point and interval estimates will be provided. 3 months
Secondary Overall survival Will be compared using Fisher's exact test, and point and interval estimates will be provided. From randomization to death due to any cause, assessed up to 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A